Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Methylpseudoephedrine
2. N-methylephedrine
3. N-methylephedrine Hydrochloride, (r*,r*)-(+-)-isomer
4. N-methylephedrine Hydrochloride, (r*,s*)-(+-)-isomer
5. N-methylephedrine Hydrochloride, (r*,s*)-isomer
6. N-methylephedrine Hydrochloride, (r-(r*,s*))-isomer
7. N-methylephedrine Hydrochloride, (s-(r*,r*))-isomer
8. N-methylephedrine, (r*,r*)-isomer
9. N-methylephedrine, (r*,s*)-(+-)-isomer
10. N-methylephedrine, (r*,s*)-isomer
11. N-methylephedrine, (r-(r*,s*))-isomer
12. N-methylephedrine, (s-(r*,r*))-isomer
1. 552-79-4
2. (1r,2s)-2-(dimethylamino)-1-phenylpropan-1-ol
3. (-)-n-methylephedrine
4. Dl-methylephedrine
5. Methylephedrine, (+/-)-
6. Methylephedrine, Dl-
7. Shs9pgq2ls
8. (+/-)-methylephedrine
9. (1r,2s)-2-dimethylamino-1-phenyl-1-propanol
10. (+/-)-n-methylephedrine
11. 60vh42a1kj
12. (1r,2s)-2-(dimethylamino)-1-phenyl-1-propanol
13. N-methyl (-)ephedrine
14. Nsc-760389
15. Tybraine
16. Methylephedrine ((1r,2s)-methylephedrine)
17. (1rs,2rs)-2-dimethylamino-1-phenylpropan-1-ol
18. Einecs 209-022-7
19. Methylephedrine [inn:ban]
20. Unii-60vh42a1kj
21. L-erythro-2-dimethylamino-1-phenylpropanol
22. (1s,2s)-(+)-n-methylephedrine
23. Ncgc00095782-01
24. 1201-56-5
25. L-erythro-alpha-(1-dimethylaminoethyl)benzylalkohol
26. (-)-methylephedrine
27. Methylephedrine (ban)
28. Spectrum_000431
29. Unii-shs9pgq2ls
30. Spectrum2_001196
31. Spectrum3_000671
32. Spectrum4_000739
33. Spectrum5_001055
34. N-methylephedrine Dl-form
35. Dsstox_cid_25992
36. Dsstox_rid_81277
37. Dsstox_gsid_45992
38. Schembl99673
39. Bspbio_002361
40. Kbiogr_001038
41. Kbioss_000911
42. N-methyl(-)ephedrine
43. Zinc491
44. Divk1c_000283
45. Spectrum2300220
46. Spbio_001271
47. N-methylephedrine [mi]
48. Chembl445001
49. Dtxsid7045992
50. Methylephedrine [who-dd]
51. (1r,2s)-(-)n-methylephedrine
52. Hms500o05
53. Kbio1_000283
54. Kbio2_000911
55. Kbio2_003479
56. Kbio2_006047
57. Kbio3_001581
58. Chebi:113556
59. Ninds_000283
60. Hms3264g05
61. Pharmakon1600-02300220
62. N-methyl-(-)ephedrine-[1r,2s]
63. Einecs 214-859-6
64. Tox21_111521
65. Benzenemethanol, Alpha-((1s)-1-(dimethylamino)ethyl)-, (alphar)-
66. Ccg-39547
67. Nsc760389
68. Akos006281830
69. Db11278
70. N-methylephedrine Dl-form [mi]
71. Nsc 760389
72. Idi1_000283
73. N-methylephedrine; Aif; Ce0; Corrdec
74. Ncgc00178692-01
75. Ncgc00178692-02
76. Ncgc00178692-04
77. Ncgc00181086-01
78. Ac-15988
79. Cas-552-79-4
80. (1r,2s)-(-)-n-methylephedrine, 99%
81. Ft-0770746
82. D08206
83. Ab00052416_02
84. Q2331543
85. Brd-k82236108-001-02-3
86. Brd-k82236108-001-03-1
87. Brd-k82236108-001-04-9
88. (r*,s*)-(1)-alpha-(1-(dimethylamino)ethyl)benzyl Alcohol
89. Methylephedrine ((1r,2s)-methylephedrine) 1.0 Mg/ml In Methanol
90. Benzenemethanol, .alpha.-((1r)-1-(dimethylamino)ethyl)-, (.alpha.s)-rel-
91. Benzenemethanol, Alpha-((1s)-1-(dimethylamino)ethyl)-, (.alpha.r)-
92. (1r,2s)-(-)-n--methylephedrine Solution, 1.0 Mg/ml In Methanol, Ampule Of 1 Ml, Certified Reference Material
| Molecular Weight | 179.26 g/mol |
|---|---|
| Molecular Formula | C11H17NO |
| XLogP3 | 1.7 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 2 |
| Rotatable Bond Count | 3 |
| Exact Mass | 179.131014166 g/mol |
| Monoisotopic Mass | 179.131014166 g/mol |
| Topological Polar Surface Area | 23.5 Ų |
| Heavy Atom Count | 13 |
| Formal Charge | 0 |
| Complexity | 141 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Used as an antitussive and decongestant.
This drugs acts as an antitussive, bronchodilator, and adrenergic receptor agonist. It stimulates the alpha and beta adrenergic receptors, relieving cough and congestion. As with other adrenomimetic amines, the drugs in this class are much less potent than norepinephrine itself. Members of this class of drugs increase both systolic and diastolic blood pressure, cardiac contractility, and cardiac output; in general, however, they do not increase heart rate. Bronchial smooth muscle relaxation of prolonged duration occurs, and pupils dilate.
Absorption
Methylephedrine is rapidly absorbed following oral administration. Peak plasma concentrations of ephedrine (from which methylephedrine is derived) occur 2-3h after administration. Due to the fact that methylephedrine is a derivative of ephedrine, peak plasma concentrations are likely similar.
Route of Elimination
The primary compound excreted in urine is unchanged methylephedrine (33-40% of dose), followed by the metabolite _methylephedrine-N-oxide_ (15% of dose), and approximately 8% of the dose excreted as ephedrine after 24 hours. About 70% of the dose is excreted in the urine as metabolites over 72 hours. Alkaline urine reduces elimination to 20-35% of the dose.
Volume of Distribution
Ephedrine: 2.5-3.0 L/kg. Methylephedrine is a derivative of ephedrine and quickly distributed throughout the body.
Methylephedrine is metabolized to give ephedrine and norephedrine.
3-6 hours (Ephedrine).
The pharmacology of methylephedrine is similar to that of other members of the ephedra alkaloid class of drugs. These compounds are sympathomimetic amines because they mimic the effects of the catecholamines on the sympathetic nervous system. These alkaloids permeate the blood-brain barrier and have a direct central nervous system stimulant effect with peripheral effects; the peripheral effects are indirect and primarily mediated by norepinephrine release. Methylephedrine expands the bronchia by relaxing the bronchial muscles. The decrease in urination with sympathomimetic use is increased through activation of the alpha-adrenoceptors of the smooth muscles of the bladder.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
ABOUT THIS PAGE
A CAS-552-79-4 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CAS-552-79-4, including repackagers and relabelers. The FDA regulates CAS-552-79-4 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CAS-552-79-4 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of CAS-552-79-4 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A CAS-552-79-4 supplier is an individual or a company that provides CAS-552-79-4 active pharmaceutical ingredient (API) or CAS-552-79-4 finished formulations upon request. The CAS-552-79-4 suppliers may include CAS-552-79-4 API manufacturers, exporters, distributors and traders.
click here to find a list of CAS-552-79-4 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A CAS-552-79-4 written confirmation (CAS-552-79-4 WC) is an official document issued by a regulatory agency to a CAS-552-79-4 manufacturer, verifying that the manufacturing facility of a CAS-552-79-4 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting CAS-552-79-4 APIs or CAS-552-79-4 finished pharmaceutical products to another nation, regulatory agencies frequently require a CAS-552-79-4 WC (written confirmation) as part of the regulatory process.
click here to find a list of CAS-552-79-4 suppliers with Written Confirmation (WC) on PharmaCompass.
CAS-552-79-4 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of CAS-552-79-4 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right CAS-552-79-4 GMP manufacturer or CAS-552-79-4 GMP API supplier for your needs.
A CAS-552-79-4 CoA (Certificate of Analysis) is a formal document that attests to CAS-552-79-4's compliance with CAS-552-79-4 specifications and serves as a tool for batch-level quality control.
CAS-552-79-4 CoA mostly includes findings from lab analyses of a specific batch. For each CAS-552-79-4 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
CAS-552-79-4 may be tested according to a variety of international standards, such as European Pharmacopoeia (CAS-552-79-4 EP), CAS-552-79-4 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (CAS-552-79-4 USP).
LOOKING FOR A SUPPLIER?
